A fast-paced discussion on how cross-modality partnerships — spanning peptides, oligonucleotides, and conjugates — are transforming therapeutic discovery and development. Panellists will share perspectives on integrated science, manufacturing, entrepreneurship, and the role of consultancy in accelerating innovation from concept to clinic.
Moderator:
CHARLES JOHANNES, Co-Founder & President, Peptide Drug Hunting Consortium
Panellists:
HANNAH BOLT, Head of Peptide Discovery, Director, AstraZeneca
MARK ECCLESTON, Chief Executive Officer, ValiRx
ALASTAIR HAY, Vice President, Almac
ANDERS DAHLEN, Senior Director, AstraZeneca
